---
title: "Lyell Immunopharma, Inc. (LYEL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LYEL.US.md"
symbol: "LYEL.US"
name: "Lyell Immunopharma, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T17:50:28.814Z"
locales:
  - [en](https://longbridge.com/en/quote/LYEL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LYEL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LYEL.US.md)
---

# Lyell Immunopharma, Inc. (LYEL.US)

## Company Overview

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.lyell.com](https://www.lyell.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: D (0.70)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 245 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -52.31% |  |
| Net Profit YoY | 26.34% |  |
| P/B Ratio | 1.38 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 376353612.12 |  |
| Revenue | 31000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -80.76% | E |
| Profit Margin | -794858.06% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | -52.31% | E |
| Net Profit YoY | 26.34% | B |
| Total Assets YoY | -18.42% | E |
| Net Assets YoY | -18.68% | E |
| Cash Flow Margin | 54.30% | C |
| OCF YoY | -52.31% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 21.95% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Lyell Immunopharma, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-52.31%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "26.34%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.38",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "376353612.12",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "31000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-80.76%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-794858.06%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-52.31%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "26.34%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-18.42%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-18.68%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "54.30%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-52.31%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "21.95%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.53 | 218/386 | - | - | - |
| PB | 1.38 | 131/386 | 1.81 | 1.17 | 0.52 |
| PS (TTM) | 12140.44 | 305/386 | 13388.87 | 8911.65 | 2703.86 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-08T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 43% |
| Overweight | 2 | 29% |
| Underweight | 1 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 16.84 |
| Highest Target | 49.00 |
| Lowest Target | 12.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LYEL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LYEL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LYEL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LYEL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**